Literature DB >> 28848907

Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus.

Robert A Wise1, Russell A Acevedo2, Antonio R Anzueto3, Nicola A Hanania4, Fernando J Martinez5, Jill A Ohar6, Donald P Tashkin7.   

Abstract

Determining which patients with COPD may benefit from a nebulized long-acting beta2-agonist (LABA) is a challenge in current practice. In the absence of strong clinical guidelines addressing this issue, an expert panel convened to develop guiding principles for the use of nebulized LABA therapy in patients with COPD. This article summarizes these guiding principles and other practical issues discussed during a roundtable meeting.

Entities:  

Keywords:  LABA; copd; copd,bronchodilator; long-acting beta2-agonists; maintenance therapy; nebulization

Year:  2016        PMID： 28848907      PMCID： PMC5560246          DOI： 10.15326/jcopdf.4.1.2016.0141

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN： 2372-952X


  83 in total

1.  Reducing excess readmissions: promising effect of hospital readmissions reduction program in US hospitals.

Authors:  Ning Lu; Kuo-Cherh Huang; James A Johnson
Journal:  Int J Qual Health Care       Date:  2015-11-15       Impact factor: 2.038

2.  A prospective study of chronic obstructive pulmonary disease and the risk for mild cognitive impairment.

Authors:  Balwinder Singh; Michelle M Mielke; Ajay K Parsaik; Ruth H Cha; Rosebud O Roberts; Paul D Scanlon; Yonas E Geda; Teresa J Christianson; V Shane Pankratz; Ronald C Petersen
Journal:  JAMA Neurol       Date:  2014-05       Impact factor: 18.302

Review 3.  Cognitive function in COPD.

Authors:  J W Dodd; S V Getov; P W Jones
Journal:  Eur Respir J       Date:  2010-04       Impact factor: 16.671

4.  Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.

Authors:  Donald A Mahler; Laurie A Waterman; Joseph Ward; Alex H Gifford
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-06-08       Impact factor: 2.849

5.  Understanding why patients with COPD get readmitted: a large national study to delineate the Medicare population for the readmissions penalty expansion.

Authors:  Tina Shah; Matthew M Churpek; Marcelo Coca Perraillon; R Tamara Konetzka
Journal:  Chest       Date:  2015-05       Impact factor: 9.410

6.  Inhaled therapy in elderly COPD patients; time for re-evaluation?

Authors:  Sheba Jarvis; Philip W Ind; Robert J Shiner
Journal:  Age Ageing       Date:  2007-01-31       Impact factor: 10.668

7.  Outpatient follow-up visit and 30-day emergency department visit and readmission in patients hospitalized for chronic obstructive pulmonary disease.

Authors:  Gulshan Sharma; Yong-Fang Kuo; Jean L Freeman; Dong D Zhang; James S Goodwin
Journal:  Arch Intern Med       Date:  2010-10-11

8.  Misuse of respiratory inhalers in hospitalized patients with asthma or COPD.

Authors:  Valerie G Press; Vineet M Arora; Lisa M Shah; Stephanie L Lewis; Krystal Ivy; Jeffery Charbeneau; Sameer Badlani; Edward Nareckas; Edward Naurekas; Antoinette Mazurek; Jerry A Krishnan
Journal:  J Gen Intern Med       Date:  2011-01-20       Impact factor: 5.128

9.  Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters.

Authors:  L Pekka Malmberg; Paula Rytilä; Pertti Happonen; Tari Haahtela
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-08-09

Review 10.  Interventions to reduce rehospitalizations after chronic obstructive pulmonary disease exacerbations. A systematic review.

Authors:  Valentin Prieto-Centurion; Michael A Markos; Norma I Ramey; Hélène A Gussin; Sharmilee M Nyenhuis; Min J Joo; Bharati Prasad; Nina Bracken; Robert Didomenico; Patrick O Godwin; Howard A Jaffe; Ravi Kalhan; Alan S Pickard; Barry R Pittendrigh; Bruce Schatz; Jamie L Sullivan; Byron M Thomashow; Mark V Williams; Jerry A Krishnan
Journal:  Ann Am Thorac Soc       Date:  2014-03
View more
  4 in total

1.  Nebulized Long-Acting Beta2-Agonists: More Than Just Bridging Gaps in the Management of Symptomatic COPD.

Authors:  Daniel A Gerardi; Nicholas J Gross
Journal:  Chronic Obstr Pulm Dis       Date:  2017-01-05

2.  Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment.

Authors:  Bartolome R Celli; Maryam Navaie; Zhun Xu; Soojin Cho-Reyes; Carole Dembek; Todd P Gilmer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-05-15

3.  Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis.

Authors:  Maryam Navaie; Carole Dembek; Soojin Cho-Reyes; Karen Yeh; Bartolome R Celli
Journal:  Chron Respir Dis       Date:  2020 Jan-Dec       Impact factor: 2.444

4.  Inhaler device feature preferences among patients with obstructive lung diseases: A systematic review and meta-analysis.

Authors:  Maryam Navaie; Carole Dembek; Soojin Cho-Reyes; Karen Yeh; Bartolome R Celli
Journal:  Medicine (Baltimore)       Date:  2020-06-19       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.